Asia-Pacific is expected to grow at the fastest CAGR during 2025-2034
The firm is selling a controlling stake in its Opella consumer health firm to focus on its science-driven pharma business, and CEO Paul Hudson is bullish about making Sanofi the worlds leading immunology company both through internal development and through dealmaking
In the first half of 2025, Mounjaro sales alone approached several billion dollars, putting it on track to challenge Novos Wegovy/Ozempic for the highest sales in the weight loss/diabetes class
July 12, 2025
Sustained release is achieved by incorporating exendin-4 into 0.06 mm diameter biodegradable microspheres containing 50:50 poly (D,L-lactide-co-glycolide) (PLG) polymer and sucrose
In 2025, the company delivered a solid +8.56% YoY revenue growth, driven by its immunology portfolio: Skyrizi ($17.56B) continues to surge with strong uptake across psoriasis and IBD, Rinvoq ($8.3B) is expanding rapidly across multiple inflammatory conditions, while Humira ($4.54B) continues to decline following loss of exclusivity marking a clear shift toward newer growth assets
